Sale

Actinic Keratosis Treatment Market

Global Actinic Keratosis Treatment Market Size, Share, Growth, Analysis: By Treatment Type: Topical Treatments, Photodynamic Therapy (PDT), Cryotherapy, Chemical Peels, Laser Therapy, Others; By End User: Hospitals, Dermatology Clinics, Others; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Actinic Keratosis Treatment Market Outlook

The actinic keratosis treatment market size attained a value of USD 7.40 billion in 2023 driven by environmental factors such as the depletion of ozone and prolonged sun exposure environmental factors such as the depletion of ozone and prolonged sun exposure. The market is anticipated to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to attain a value of USD 10.71 billion by 2032.

 

Global Actinic Keratosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The increased prevalence of actinic keratosis, driven by environmental factors such as the depletion of ozone and prolonged sun exposure, is the major factor driving the growth of the actinic keratosis treatment industry globally.

 

Market Segmentation

Actinic keratosis refers to the growth of scaly patch on skin that grows out of years of sun exposure. Chances of its occurrence are more in people who are exposed to sunlight, and, thus, are at higher risk of actinic keratosis. The growth of actinic keratosis could lead to squamous cell carcinoma, which is a type of cancer.

 

Global Actinic Keratosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global actinic keratosis treatment industry can be broadly categorised based on segments like therapy, drug class, end-uses, and regions.

  • Therapy:
    • Topical
    • Surgery
    • Photodynamic Therapy
  • Drug Class:
    • Nucleoside Metabolic Inhibitors
    • Nonsteroidal Anti-Inflammatory Drugs
    • Immune Response Modifiers
    • Photoenhancers
    • Others
  • End-Use:
    • Hospitals
    • Private Clinics
    • Homecare
    • Others

The EMR report looks into the regional actinic keratosis treatment markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific

 

Market Analysis

It is projected that the increasing prevalence of actinic keratosis, the rising acceptance of minimally invasive therapeutic procedures, the availability of appropriate medical coverage, and a growing geriatric population are the major drivers of the market growth. However, the risk factors associated with available treatment options may hamper industry growth over the forecast period.

The hospitals segment, among other end uses, dominates the industry owing to the ease of accessibility, rise in healthcare infrastructure, and the growing number of patients.

 

Global Actinic Keratosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global actinic keratosis treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bausch Health Companies Inc.
  • LEO Pharma A/S
  • Almirall, S.A
  • Biofrontera
  • Hill Dermaceuticals, Inc.
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • End User
  • Treatment Channel
  • Distribution Channel
  • Region
Breakup by Treatment Type
  • Topical Treatments
  • Photodynamic Therapy (PDT)
  • Cryotherapy
  • Chemical Peels
  • Laser Therapy
  • Others
Breakup by End User
  • Hospitals
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Homecare
  • Others (Research Institutes, Academic Institutes, etc.)
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Distribution Channel
  • Direct Tenders
  • Retail Sales
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Galderma S.A.
  • LEO Pharma
  • Bausch Health Companies Inc.
  • Almirall, S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Perrigo Company plc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Valeant Pharmaceuticals International, Inc.
  • Teva Pharmaceutical Industries Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1     Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Actinic Keratosis Diseases Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Actinic Keratosis Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Actinic Keratosis Epidemiology (2016-2031)
    5.3    Europe Actinic Keratosis Epidemiology (2016-2031)
    5.4    Asia-Pacific Actinic Keratosis Epidemiology (2016-2031)
    5.5    Latin America Actinic Keratosis Epidemiology (2016-2031)
    5.6    Middle East & Africa Actinic Keratosis Epidemiology (2016-2031)
6    Global Actinic Keratosis Treatment Market Overview 
    6.1    Global Actinic Keratosis Treatment Market Historical Value (2017-2023)
    6.2    Global Actinic Keratosis Treatment Market Forecast Value (2024-2032)
7    Global Actinic Keratosis Treatment Market Landscape
    7.1    Global Actinic Keratosis Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Actinic Keratosis Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by End User
        7.2.3    Analysis by Distribution Channel
8    Actinic Keratosis Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Actinic Keratosis Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Actinic Keratosis Treatment Market Segmentation
    11.1    Global Actinic Keratosis Treatment Market by Treatment Type
        11.1.1    Market Overview
        11.1.2    Topical Treatments
            11.1.2.1    Fluorouracil
            11.1.2.2    Imiquimod
            11.1.2.3    Diclofenac
            11.1.2.4    Ingenol mebutate
        11.1.3    Photodynamic Therapy (PDT)
        11.1.4    Cryotherapy
        11.1.5    Chemical Peels
        11.1.6    Laser Therapy
        11.1.7    Others
    11.2    Global Actinic Keratosis Treatment Market by End User
        11.2.1    Market Overview
        11.2.2    Hospitals
        11.2.3    Dermatology Clinics
        11.2.4    Ambulatory Surgical Centers
        11.2.5    Homecare
        11.2.6    Others (Research Institutes, Academic Institutes, etc.)
    11.3    Global Actinic Keratosis Treatment Market by Treatment Channel
        11.3.1    Market Overview
        11.3.2    Public
        11.3.3    Private
    11.4    Global Actinic Keratosis Treatment Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Direct Tenders
        11.4.3    Retail Sales
        11.4.4    Others
    11.5    Global Actinic Keratosis Treatment Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Actinic Keratosis Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Actinic Keratosis Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Actinic Keratosis Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Actinic Keratosis Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Actinic Keratosis Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Galderma S.A.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    LEO Pharma
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Bausch Health Companies Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Almirall, S.A.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Sun Pharmaceutical Industries Ltd.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Perrigo Company plc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    GlaxoSmithKline plc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Novartis AG
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Valeant Pharmaceuticals International, Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Teva Pharmaceutical Industries Ltd.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Actinic Keratosis Treatment Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for actinic keratosis reached a value of USD 7.40 billion.

The market is anticipated to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to reach a value of USD 10.71 billion by 2032.

The major drivers of the market include the increasing prevalence of actinic keratosis, growing acceptance of minimally invasive therapeutic procedures, and increasing geriatric population.

Depletion of ozone layer leading to an increased incidence of actinic keratosis is the key industry trend propelling the growth of the market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading therapies of actinic keratosis treatment in the market are topical, surgery, and photodynamic therapy.

The major drug classes of actinic keratosis treatment in the industry are nucleoside metabolic inhibitors, nonsteroidal anti-inflammatory drugs, immune response modifiers, and photoenhancers, among others.

The significant end use sectors of actinic keratosis treatment in the market are hospitals, private clinics, and homecare, among others.

The major players in the industry are Bausch Health Companies Inc., LEO Pharma A/S, Almirall, S.A., Biofrontera, and Hill Dermaceuticals Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER